About molecular partners ag - MOLN
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
MOLN At a Glance
Molecular Partners AG
Wagistrasse 14
Schlieren, Zurich 8952
| Phone | 41-44-755-77-00 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -74,234,824.14 | |
| Sector | Health Technology | Employees | 149 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MOLN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.608 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.773 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.093 |
MOLN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -498,220.296 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MOLN Liquidity
| Current Ratio | 8.785 |
| Quick Ratio | 8.785 |
| Cash Ratio | 8.439 |
MOLN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -48.869 |
| Return on Equity | -57.616 |
| Return on Total Capital | -70.033 |
| Return on Invested Capital | -56.642 |
MOLN Capital Structure
| Total Debt to Total Equity | 4.536 |
| Total Debt to Total Capital | 4.339 |
| Total Debt to Total Assets | 3.569 |
| Long-Term Debt to Equity | 3.035 |
| Long-Term Debt to Total Capital | 2.903 |